Загрузка...
A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer
BACKGROUND: Use of radiopharmaceutical may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides clinical benefit for patients with advanced castrate-sensitive prostat...
Сохранить в:
| Опубликовано в: : | Cancer |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4270821/ https://ncbi.nlm.nih.gov/pubmed/25155428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28971 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|